Views & Analysis Highs and lows in regenerative medicine How developments in gene editing and screening technology are advancing regenerative medicine.
News EU regulators back blood cancer stem cell therapy Molmed's treatment aims to prevent reduce risk of graft-versus-host disease.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
